Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10977
Title: A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
Austin Authors: Proietto, Joseph ;Rissanen, A;Harp, J B;Erondu, N;Yu, Q;Suryawanshi, S;Jones, Mark E;Johnson-Levonas, A O;Heymsfield, S B;Kaufman, K D;Amatruda, J M
Affiliation: Department of Medicine, University of Melbourne, Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia
Issue Date: 9-Mar-2010
Publication information: International Journal of Obesity (2005) 2010; 34(8): 1243-54
Abstract: To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients.Multicenter, double-blind, randomized, placebo-controlled study.Patients >or=18 years old, BMI 27-43 kg m(-2), were randomized to placebo (n=209) or taranabant 0.5 mg (n=207), 1 mg (n=208) or 2 mg given orally once daily (n=417) for 52 weeks.Key efficacy measurements included body weight (BW), waist circumference (WC), lipid endpoints and glycemic endpoints.Based on a last observation carried forward analysis of the all-patients-treated population, mean change in BW for taranabant 0.5, 1, and 2 mg and placebo was -5.4, -5.3, -6.7 and -1.7 kg, respectively (P<0.001 for all doses vs placebo). The proportions of patients who lost at least 5 and 10% of their baseline BW at week 52 were significantly higher for all taranabant doses vs placebo (P<0.001 for all doses). Reductions in WC, percentage of body fat, and triglycerides were significant for taranabant 2 mg and in triglycerides for taranabant 1 mg vs placebo. There was no effect of taranabant vs placebo on other lipid or glucose-related endpoints. Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group. Irritability was higher and statistically significant in all taranabant groups compared with the placebo group.All three doses of taranabant-induced clinically meaningful and statistically significant weight loss. Incidences of adverse experiences in organ systems known to express CB1R were higher in taranabant groups.
Gov't Doc #: 20212496
URI: https://ahro.austin.org.au/austinjspui/handle/1/10977
DOI: 10.1038/ijo.2010.38
Journal: International journal of obesity (2005)
URL: https://pubmed.ncbi.nlm.nih.gov/20212496
Type: Journal Article
Subjects: Administration, Oral
Adult
Aged
Aged, 80 and over
Amides.administration & dosage
Anti-Obesity Agents.administration & dosage
Body Weight.drug effects
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Male
Middle Aged
Obesity.drug therapy
Pyridines.administration & dosage
Questionnaires
Receptor, Cannabinoid, CB1.antagonists & inhibitors
Weight Loss
Young Adult
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.